IDH2 and neoplasm: Compared to the initial grossly resected tumor specimen, the recurrent tumor possessed loss of heterozygosity of 1p, 10q, 17q, and 19q chromosomes, as well as a new C228T TERT promoter mutation, while the status of wild-type IDH1/IDH2 and mutant BRAF V600E was unchanged (13).